MedTrace Logo

Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients

NCT01736033 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 545

Last updated 2014-05-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical efficacy of alpha-blocker monotherapy and alpha-blocker + 5-alpha reductase inhibitor combination therapy in benign prostate hyperplasia patients, and suggest guidelines of the combination therapy.

Conditions

  • Benign Prostate Hyperplasia

Interventions

DRUG

Tamsulosin

1 tablet(0.2mg) orally q.d.

DRUG

Finasteride

1 tablet(5mg) orally q.d.

DRUG

Placebo

1 tablet(0.2mg) orally q.d.

Sponsors & Collaborators

  • Astellas Pharma Korea, Inc.

    collaborator INDUSTRY

  • Medical Research Collaborating Center, Seoul, Korea

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Soo Woong Kim, M.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2017-02-28
Completion
2017-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01736033 on ClinicalTrials.gov